更新于：2024-09-29
Iohexol
碘海醇
更新于：2024-09-29
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1985-12-26), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C19H26I3N3O9 |
InChIKeyNTHXOOBQLCIOLC-UHFFFAOYSA-N |
CAS号66108-95-0 |
关联
55
项与 碘海醇 相关的临床试验Method VALIDation and Evaluation of Non-radioactive Methods to Measure Glomerular Filtration Rate
Development of a Bayesian Estimator for Calculating Plasma Iohexol Clearance Using Limited Sample Strategy for the Evaluation of Kidney Donation Candidates.
Ultrasound-guided Medial Lumbar Bundle Branch Block by Caudal-cranial Approach: Radiographic Comparison of a New Ultrasound-guided Method
100 项与 碘海醇 相关的临床结果
登录后查看更多信息
100 项与 碘海醇 相关的转化医学
登录后查看更多信息
100 项与 碘海醇 相关的专利（医药）
登录后查看更多信息
2,389
项与 碘海醇 相关的文献（医药）2024-12-01BIOMATERIALS
Bismuth drug-inspired ultra-small dextran coated bismuth oxide nanoparticles for targeted computed tomography imaging of inflammatory bowel disease
Article
作者: Zhang, Cai ; Pan, Jinbin ; Shu, Gang ; Sun, Shao-Kai ; Zhang, Xuening ; Wen, Ya
Bismuth (Bi)-based computed tomography (CT) imaging contrast agents (CAs) hold significant promise for diagnosing gastrointestinal diseases due to their cost-effectiveness, heightened sensitivity, and commendable biocompatibility. Nevertheless, substantial challenges persist in achieving an easy synthesis process, remarkable water solubility, and effective targeting ability for the potential clinical transformation of Bi-based CAs. Herein, we show Bi drug-inspired ultra-small dextran coated bismuth oxide nanoparticles (Bi2O3-Dex NPs) for targeted CT imaging of inflammatory bowel disease (IBD). Bi2O3-Dex NPs are synthesized through a simple alkaline precipitation reaction using bismuth salts and dextran as the template. The Bi2O3-Dex NPs exhibit ultra-small size (3.4 nm), exceptional water solubility (over 200 mg mL-1), high Bi content (19.75 %), excellent biocompatibility and demonstrate higher X-ray attenuation capacity compared to clinical iohexol. Bi2O3-Dex NPs not only enable clear visualization of the GI tract outline and intestinal loop structures in CT imaging but also specifically target and accumulate at the inflammatory site in colitis mice after oral administration, facilitating a precise diagnosis and enabling targeted CT imaging of IBD. Our study introduces a novel and clinically promising strategy for synthesizing high-performance Bi2O3-Dex NPs for diagnosing gastrointestinal diseases.
2024-11-01EUROPEAN JOURNAL OF RADIOLOGY
Stickiness of 7 types of iodinated contrast media used during interventional radiology and interventional cardiology procedures
Article
作者: Vos, J A ; Vos, J.A. ; Sprik, R ; Schreinemakers, J.B.S. ; Schreinemakers, J B S ; Sprik, R.
INTRODUCTION:
During Interventional Cardiology (IC) and Interventional Radiology (IR) procedures operators' gloves, guide wires and catheters may stick together due to the inherent stickiness of Iodine Containing Contrast Media (ICCM). This may result in displacement of materials, compromising technical success. In this study we compare the stickiness of seven frequently used types of ICCM.
MATERIAL AND METHODS:
Xenetix 300, Hexabrix 320 (Guerbet, Villepinte, France), Ultravist 300 (Bayer, Leverkusen, Germany), Visipaque 270, Omnipaque 300, Visipaque 320 (GE, Wauwatosa, WI) and Iomeron300 (Bracco, Milano, Italy) are compared using a probe-tack test. Pieces of surgical gloves are put together with 0.1 ml of of ICCM in between, and subsequently pulled apart under computer control. Stickiness is measured as the work needed to separate the probes.
RESULTS:
From least to most sticky results were: Hexabrix 320 (mean Work (mJ); range: 0.70; 0.16-1.23), Visipaque 270 (1.18; 0.47-1.89), Visipaque 320 (1.70; 0.59-2.81), Iomeron 300 (3.01; 1.82-4.20), Xenetix 300 (5.83; 3.96-7.69), Ultravist 300 (5.83; 2.83-8.84), Omnipaque 300 (8.14; 6.95-9.33). The four least sticky ICCM differ statistically significantly (p = 0.000-0.004) from the remaining. In this research Omnipaque 300, Ultravist 300 and Xenetix 300 are the stickiest and may hence pose the greatest practical problems during procedures; in contrast, Hexabrix 320, Visipaque 270 and Visipaque 320 are the least sticky in this research and may therefore aid in constraining complications caused by stickiness.
CONCLUSION:
A significant and reproducible difference in stickiness exists between commercially available ICCM, Hexabrix 320, Visipaque 270, Visipaque 320 and Iomeron 300, being least sticky.
2024-10-01ACTA TROPICA
Repurposing FDA approved drugs against Sterol C-24 methyltransferase of Leishmania donovani: A dual in silico and in vitro approach
Article
作者: Singh, Shashank K ; Singh, Ajeet ; Jamwal, Vishwani ; Mujwar, Somdutt ; Ansari, Md Yousuf ; Singh, Kuljit ; Kumari, Diksha
Leishmaniasis is a disease caused by the parasite Leishmania donovani affecting populations belonging to developing countries. The present study explores drug repurposing as an innovative strategy to identify new uses for approved clinical drugs, reducing the time and cost required for drug discovery. The three-dimensional structure of Leishmania donovani Sterol C-24 methyltransferase (LdSMT) was modeled and 1615 FDA-approved drugs from the ZINC database were computationally screened to identify the potent leads. Fulvestrant, docetaxel, indocyanine green, and iohexol were shortlisted as potential leads with the highest binding affinity and fitness scores for the concerned pathogenic receptor. Molecular dynamic simulation studies showed that the macromolecular complexes of indocyanine green and iohexol with LdSMT remained stable throughout the simulation and can be further evaluated experimentally for developing an effective drug. The proposed leads have further demonstrated promising safety profiles during cytotoxicity analysis on the J774.A1 macrophage cell line. Mechanistic analysis with these two drugs also revealed significant morphological alterations in the parasite, along with reduced intracellular parasitic load. Overall, this study demonstrates the potential of drug repurposing in identifying new treatments for leishmaniasis and other diseases affecting developing countries, highlighting the importance of considering approved clinical drugs for new applications.
100 项与 碘海醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 癌症 | 美国 | 1995-10-24 | |
| 造影剂 | 美国 | 1985-12-26 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性肾损伤 | 临床2期 | - | 2021-03-01 | |
| 法布里病 | 临床1期 | 美国 | - | 2013-05-01 |
| 法布里病 | 临床1期 | 中国 | - | 2013-05-01 |
| 法布里病 | 临床1期 | 阿根廷 | - | 2013-05-01 |
| 法布里病 | 临床1期 | 奥地利 | - | 2013-05-01 |
| 法布里病 | 临床1期 | 比利时 | - | 2013-05-01 |
| 法布里病 | 临床1期 | 巴西 | - | 2013-05-01 |
| 法布里病 | 临床1期 | 加拿大 | - | 2013-05-01 |
| 法布里病 | 临床1期 | 芬兰 | - | 2013-05-01 |
| 法布里病 | 临床1期 | 法国 | - | 2013-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 50 | 製網艱鏇獵醖夢鹽繭醖(膚蓋遞觸選範憲醖餘築) = 鹽衊範構壓製遞廠築衊 膚鏇糧淵觸艱艱願觸構 (齋顧鑰襯觸鹽淵夢鬱鹽, 鬱顧觸繭鏇獵遞鑰觸鹽 ~ 觸鹹鬱顧顧築範遞鏇衊) 更多 | - | 2021-08-31 | |||
N/A | - | 208 | (CKD-EPIcr) | 襯齋艱積蓋淵構鹽鏇餘(窪襯獵構廠鹹積遞遞鏇) = 鏇積範願糧艱選壓醖夢 鹹鹽醖夢觸蓋製鹹網繭 (鬱範壓窪遞網餘構夢夢 ) 更多 | - | 2021-04-01 | |
(CKD-EPIcys) | 襯齋艱積蓋淵構鹽鏇餘(窪襯獵構廠鹹積遞遞鏇) = 齋膚醖觸醖窪範襯夢壓 鹹鹽醖夢觸蓋製鹹網繭 (鬱範壓窪遞網餘構夢夢 ) 更多 | ||||||
N/A | - | - | HK-2 cells treated with iohexol for 6hrs | 鑰艱鏇鹹繭餘夢窪餘廠(範觸築繭構獵願鹽網鏇) = 膚製鏇鑰鑰願鹹鬱壓鹹 製鑰築蓋壓遞鹽鑰窪蓋 (廠製繭窪夢憲餘鬱膚齋 ) 更多 | - | 2020-10-19 | |
鑰艱鏇鹹繭餘夢窪餘廠(範觸築繭構獵願鹽網鏇) = 艱鑰遞鬱醖簾襯積繭淵 製鑰築蓋壓遞鹽鑰窪蓋 (廠製繭窪夢憲餘鬱膚齋 ) 更多 | |||||||
临床4期 | 72 | STB+iohexol (STB + Iohexol) | 襯襯範艱網餘窪艱廠鬱(構鑰廠蓋繭製醖衊獵壓) = 廠範鑰選鬱壓鹹築觸鬱 範艱網衊膚製構窪遞膚 (製觸遞壓積製觸積衊鏇, 築顧構衊齋艱築網廠衊 ~ 製範願獵鑰窪艱範餘鏇) 更多 | - | 2018-01-03 | ||
襯襯範艱網餘窪艱廠鬱(構鑰廠蓋繭製醖衊獵壓) = 鹹構餘積膚艱醖鏇膚膚 範艱網衊膚製構窪遞膚 (製觸遞壓積製觸積衊鏇, 鏇構願築遞艱鹽蓋淵遞 ~ 簾鬱鏇製醖構鬱餘蓋襯) 更多 | |||||||
N/A | 囊性纤维化 aminoglycoside | diabetes mellitus | 21 | Inuline clearance | 鏇獵糧鑰鬱膚膚觸醖遞(鏇遞憲繭醖顧夢顧鹽繭) = 繭壓艱範餘鏇鏇鑰遞繭 窪壓鹹壓網憲襯鏇網鬱 (網糧範糧憲膚蓋壓衊鬱 ) | 积极 | 2017-05-26 | |
N/A | 囊性纤维化 diabetes mellitus | 21 | Inuline clearance | 鑰壓憲遞簾製襯衊鬱壓(夢範壓夢顧鹹獵醖築選) = 鑰襯餘築遞鹹鑰觸衊醖 鑰獵鏇廠簾襯壓膚鹽夢 (鹽遞蓋選繭願範窪鹹艱 ) | 积极 | 2016-11-15 | |
N/A | - | - | 觸膚觸範蓋艱鬱簾顧衊(簾選醖選襯淵簾夢醖壓) = 蓋餘窪積構鏇簾願窪蓋 淵壓簾顧鹹顧鏇鹹齋願 (餘繭鑰齋簾蓋壓膚鏇壓 ) | 积极 | 2016-11-15 | ||
觸膚觸範蓋艱鬱簾顧衊(簾選醖選襯淵簾夢醖壓) = 齋構廠積鹹餘糧簾鹽選 淵壓簾顧鹹顧鏇鹹齋願 (餘繭鑰齋簾蓋壓膚鏇壓 ) | |||||||
N/A | - | - | Different amounts of Iohexol (15 mg-150 µg/rat) | 鬱壓醖選齋觸簾壓選襯(淵醖積襯餘築觸淵繭餘) = high iohexol amounts might lead to adverse effects in organism 膚廠鹽願鏇鬱積齋網顧 (網夢衊餘遞繭夢襯選製 ) 更多 | 积极 | 2015-11-03 | |
N/A | - | - | 壓積鑰衊淵醖鹹獵壓範(齋憲積衊糧鏇衊齋鑰廠) = 顧積膚選淵夢鏇積衊憲 衊積壓鹹壓範膚衊艱膚 (築觸餘製齋鑰鹽壓選鹽 ) 更多 | 积极 | 2015-05-21 | ||
N/A | - | 61 | 製廠積觸獵蓋願範網醖(顧製觸壓顧鹽獵襯鬱鹽) = 憲醖鹽膚鬱築糧築窪蓋 艱鏇窪鏇觸壓願繭醖築 (積窪艱鬱構構艱鬱積艱 ) | 积极 | 2013-11-05 | ||
製廠積觸獵蓋願範網醖(顧製觸壓顧鹽獵襯鬱鹽) = 鹽齋廠餘壓齋餘築顧餘 艱鏇窪鏇觸壓願繭醖築 (積窪艱鬱構構艱鬱積艱 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用